Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec, Haplogen to jointly develop anti-viral compounds
The drugs resulting from the partnership are expected to target a human protein that is vital for the spread of pathogenic viral infection in the host cell. Haplogen
The drugs resulting from the partnership are expected to target a human protein that is vital for the spread of pathogenic viral infection in the host cell. Haplogen
Data demonstrated that Complera is non-inferior to Atripla, achieving HIV RNA levels less than 50 copies/mL through 48 weeks of therapy, the primary endpoint of the study. On
As part of Series B financing, the firm has already raised about $25m from pharmaceutical major Eli Lilly and global financial services firm Fidelity. With plans underway to
Impax Laboratories and its subsidiary ThoRx Laboratories have been challenged by US-based Endo Pharmaceuticals and German’s Grunenthal on 14 November 2012, regarding the patents of Opana® ER tablets,
According to the company the increased loss is due to the $155,000 increase in general and administration expenses, a $33,000 increase in business development expenses and a $28,000
The company won regulatory authorisation to advance the trials in October, from Medsafe. Living Cell Technologies chief executive Dr Andrea Grant said the ethical approval was granted in
With the move the company plans to increase its foothold in the US with the help of existing European and US pharmaceutical regulations. SDI America president Danny Cusick
The new facility for Shanghai Promega Biological Products will replace present molecular biology reagent production site and also provide additional research, development and cGMP manufacturing capabilities for molecular
As part of a distribution agreement between Mikah and Actavis, Actavis will distribute Phendimetrazine tartrate 35 mg tablets, which are equivalent to generic version of Bontril PDM(R) 35 mg tablets.
The 25,000ft² laboratory, which represents LGC latest genomics investment, will carry out manufacturing operations of the firm’s reagents and laboratory products. LGC chief executive David Richardson said the